Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies  >  Press Releases

News : Companies

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors
05:30pPomerantz Law Firm Investigates Claims On Behalf of Investors of Gol Linhas Aereas Inteligentes S.A. - GOL
GL
05:14pPomerantz Law Firm Investigates Claims On Behalf of Investors of Strongbridge Biopharma plc - SBBP
GL
05:05pMANCHESTER UNITED : Disjointed and overrun, Man Utd slumps to loss on EPL return
AQ
04:36pPomerantz Law Firm Investigates Claims On Behalf of Investors of Nano-X Imaging Ltd. - NNOX
GL
04:05pASPEN : Investor Presentation
PU
02:46pNANO X IMAGING : ROSEN, A GLOBALLY RECOGNIZED FIRM, First Files Securities Class Action Lawsuit Against Nano-X Imaging Ltd. - NNOX
PR
02:20pLINCOLN NATIONAL : Financial Group Statement on the Death of Justice Ruth Bader Ginsburg
PU
01:45pPETRONOR E&P : Agreement with The Gambia
PU
01:45pENTERGY : Hurricane Laura Restoration Update - 9/19/20 @ 11 a.m.
PU
01:30pESMO 2020 : Cabometyx® (cabozantinib) in combination with Opdivo® (nivolumab) demonstrates significant survival benefits in patients with advanced renal cell carcinoma in pivotal Phase III CheckMate -9ER trial
PU
01:24pPETRONOR E&P : Agreement with The Gambia
AQ
01:22pACTBLUE : Ginsburg's death draws big surge of donations to Democrats
AQ
01:21pACTBLUE : Ginsburg's death draws big surge of donations to Democrats
AQ
01:05pASTRAZENECA : TAGRISSO Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer
BU
12:32pBRISTOL MYERS SQUIBB : Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial
BU
Discover
12:31pESMO 2020 : Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial
BU
12:01pMEDIA AVAILABILITY : CN Police officers available for media interviews during Rail Safety Week
AQ
12:01pMEDIA AVAILABILITY : CN Police officers available for media interviews during Rail Safety Week
GL
11:45aIMMUNOMEDICS : Trodelvyᵀᴹ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer
PU
11:45aIMMUNOMEDICS : Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvyᵀᴹ in Metastatic Urothelial Cancer
PU
11:15aINFO EDGE INDIA : Investor Conference
PU
11:14aNSP Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Insperity Inc.
GL
11:01aIMMUNOMEDICS : Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer
AQ
11:01aImmunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer
GL
10:45aROCHE : presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
PU
10:31aIMMUNOMEDICS : Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer
AQ
10:31aTrodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer
GL
10:25aNovartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation
GL
10:21aROCHE : presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
AQ
10:21aMERCK : KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
BU
10:21aGENENTECH : Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020
BU
10:20aNovartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma
GL
10:20aRoche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
GL
09:16aCOSTA'S CRUISES RETURN TO GENOA : Costa Diadema Sails Today
PR
09:00aWIIT S P A : myLoc acquisition
PU
08:55aAnnouncing Killer Mike as Keynote Speaker at UNCF/Koch Scholars Program Virtual Summit
GL
08:06aITERA : Grief As Kyerwa Pays Last Respects to Deceased Children
AQ
08:00aWALMART : Amazon among donors to QAnon-promoting lawmaker
AQ
07:58aBASEBALL : Pacific League standings (Sept. 19)
AQ
07:31aZAI LAB : Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian cancer
AQ
07:31aPhase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian cancer
GL
06:45aSTANDARD CHARTERED : We've completed our first cross-bank Letter of Credit blockchain transaction between Vietnam and Thailand
PU
06:25aG20 Trade and Investment Ministers Meeting - Press Release
PU
06:25aJSE : TEST JSE Regulatory Announcement
PU
05:20aMARSHAL LION FINANCIAL GROUP CORP : A Marshal Lion mobile app has reached many users' smartphones in record time.
EQ
03:00aAxion Receives Petition to the Court and Notice of Civil Claim
NE
02:15aELLIS MARTIN REPORT : OriginClear's (OTCMKTS:OCLN) Riggs Eckelberry on Investment Potential in Water Systems
AQ
02:15aELLIS MARTIN REPORT : OriginClear's (OTCMKTS:OCLN) Riggs Eckelberry on Investment Potential in Water Systems
AW
02:07aAUB : Entitlement to indemnity under marine transit insurance
AQ
01:50aELLIS MARTIN REPORT : Rockridge Resources (VAN:ROCK) Commences 3,000 Metre Diamond Drill Program at its High-Grade Raney Gold Project
AQ
01:50aELLIS MARTIN REPORT : Rockridge Resources Commences 3,000 Metre Diamond Drill Program at its High-Grade Raney Gold Project
AW
09/19ELLIS MARTIN REPORT : Gold Terra (VAN:YGT) (OTCMKTS:YGTFF) to Earn up to a 60% Interest on Adjacent Mining Claims to the Former Con Mine Owned by Newmont
AQ
09/19ELLIS MARTIN REPORT : Gold Terra (OTCMKTS:YGTFF) to Earn up to a 60% Interest on Adjacent Mining Claims to the Former Con Mine Owned by Newmont
AW
09/18International open ideas competition announces 3 finalists for iconic landmark in Silicon Valley
PR
09/18COVID-19 RECOVERY ANALYSIS : HVDC Converter Stations Market | Increase in Global Power Demand to Boost Market Growth | Technavio
BU
09/18AIRBUS : HTM-Helicopters to become the first operator to use the new H145 for Offshore Wind operations
PU
09/18AIRBUS : Helicopters and HTM-Helicopters have signed a contract for the purchase of two additional H145 helicopters. ...
PU
09/18ADVANTECH : Launches UNO-137 Integrated IoT Edge for Industry 4.0 Applications
PU
09/18HORIZONTAL CAROUSEL MARKET : COVID-19 Business Continuity Plan | Evolving Opportunities with Bastian Solutions LLC and Conveyors & Drives Inc. | Technavio
BU
09/18MOHAWK INDUSTRIES INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL : Kahn Swick & Foti, LLC Investigates the Officers and Directors of Mohawk Industries, Inc. - MHK
BU
1  2  3  4  5  6  7  8  9  10Next